Cargando…

Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus

Hepatitis C virus (HCV) is a bloodborne infection that is one of the leading causes of liver disease. If left untreated, HCV can lead to cirrhosis, hepatocellular carcinoma, and death. The current standard of care for HCV is a combination of pegylated-interferon (peg-IFN) and ribavirin (RBV) in whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Christine M., Mendes, Margaret, Tsunoda, Shirley, Ma, Joseph D.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Evidence on Genomic Tests
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024597/ https://www.ncbi.nlm.nih.gov/pubmed/21278901 http://dx.doi.org/10.1371/currents.RRN1207

Ejemplares similares

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)

Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy
por: Ishibe, Naoko, et al.
Publicado: (2011)

The Role of Interleukin-28b Gene Polymorphisms in Chinese Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin
por: Mi, Yin, et al.
Publicado: (2014)

DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010)

KIF6 p.Trp719Arg Testing to Assess Risk of Coronary Artery Disease and/or Statin Response
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

Oncotype DX tumor gene expression profiling in stage II colon cancer: Application: Prognostic, risk prediction
por: Webber, Elizabeth M., et al.
Publicado: (2010)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Tumor Gene Expression Profiling in Women with Breast Cancer: Test Category: Prognostic
por: Bellcross, Cecelia, et al.
Publicado: (2010)

PLoS Currents: Evidence on Genomic Tests – At the Crossroads of Translation
por: Gwinn, Marta, et al.
Publicado: (2010)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors
por: Dancik, Garrett, et al.
Publicado: (2011)

Genetic risk profiling for prediction of type 2 diabetes
por: Mihaescu, Raluca, et al.
Publicado: (2011)

Genetic Testing for Lynch Syndrome in Individuals Newly Diagnosed with Colorectal Cancer to Reduce Morbidity and Mortality from Colorectal Cancer in Their Relatives
por: Coates, Ralph, et al.
Publicado: (2011)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Cascade Screening for Familial Hypercholesterolemia (FH)
por: Ned, Renée M., et al.
Publicado: (2011)

Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics
por: Ned, Renée M.
Publicado: (2010)

Comprehensive Carrier Screening and Molecular Diagnostic Testing for Recessive Childhood Diseases
por: Kingsmore, Stephen
Publicado: (2012)

Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test
por: Ned, Renée M., et al.
Publicado: (2011)

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Terasawa, Teruhiko, et al.
Publicado: (2011)

HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010)

Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies
por: Marrone, Michael, et al.
Publicado: (2014)

Analytical and Clinical Validity Study of FirstStepDx PLUS: A Chromosomal Microarray Optimized for Patients with Neurodevelopmental Conditions
por: Hensel, Charles, et al.
Publicado: (2017)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin
por: Kalantari, Hamid, et al.
Publicado: (2019)

Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection
por: Kim, Do Young
Publicado: (2014)

Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism
por: Ekstrom, Victoria, et al.
Publicado: (2017)

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
por: Younossi, Zobair M, et al.
Publicado: (2012)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C
por: Heidari, Mehdi, et al.
Publicado: (2014)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
por: Kapol, Nattiya, et al.
Publicado: (2016)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rer054q08270049prk6iqn2sp1